ORIDIS Biomed Appoints Wolfgang Senne as Chief Financial Officer
Graz, Austria (October 2, 2006) ― ORIDIS Biomed, a biopharmaceutical
company developing targeted treatment solutions for liver diseases,
announced today that it has appointed Wolfgang Senne as Chief Financial
Officer. Prior to joining ORIDIS Biomed Wolfgang Senne held various
executive positions in the European and US life science industry,
including Siemens Medical Solutions, Carl Zeiss Medical Systems, and
GeneScan Europe AG. He takes over from acting CFO / COO Dr. Reinhold
Bayer who retires.
“I am extremely pleased about the international experience and the
operational expertise that Wolfgang is bringing to ORIDIS Biomed”, said
Peter Hecht, PhD, CEO of ORIDIS Biomed. “Wolfgang’s background in
commercialization and finances in research driven life science
industries, specifically on the US market, will help us further extend
our international presence.”
“I want to thank Reinhold for the tremendous contributions he has made
to the Company,” said Hecht. “Reinhold’s background in financial
management and administration was instrumental in successfully
developing our TISSOMICS™ research platform, and in initiating ORIDIS
Biomed’s drug development programs.”
"ORIDIS Biomed has managed to successfully commercialize its TISSOMICS™
research platform, bringing medical relevance early into the drug
development process", said Wolfgang Senne. "At the same time, ORIDIS
Biomed has applied this platform to its own drug development programs,
and I am most impressed by the potential of this approach."
Wolfgang Senne started his business life at the medical devices business
of Siemens. During his career he held several executive positions in
Europe and the USA, focusing on the development of new products and
worldwide marketing within the life science area. In 2001, he joined
GeneScan Europe AG, a biotech company focusing on microbiological
analytical systems, where he held the positions of CFO, and CEO.
Wolfgang Senne joins ORIDIS Biomed after holding interim executive
manager position in a life science start-up. He will relocate to Graz,
Austria from Germany with his family.
About TISSOMICS™
TISSOMICS™ is a proprietary disease-driven research platform enabling
the medical validation of drug discovery approaches and biomarkers.
ORIDIS Biomed has a license from the Medical University of Graz, Austria
for the commercial access to BioResource-Med biobank, one of the world’s
largest collections of diseased human tissues and associated medical
data.
TISSOMICS™ has been successfully applied in co-operations and
partnerships with leading pharmaceutical and biotechnology companies to
deliver medical validation to their drug discovery or biomarker programs
using optimized genomic and proteomic approaches.
About ORIDIS Biomed
ORIDIS Biomed is a biopharmaceutical company, developing therapeutics,
diagnostics and biomarkers (targeted treatment solutions) for liver
diseases. Therapeutic programs include primary liver cancer (hepatocellular
carcinoma, HCC), and metabolic liver diseases, such as alcoholic
steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH), where
incidence rates are rapidly increasing due to modern life-styles, while
treatment options are limited, expensive, and often ineffective.
ORIDIS Biomed uses its proprietary TISSOMICS™ platform also in its own
research and development programs. In addition, the Company
commercializes the TISSOMICS™ research platform in collaborations with
industrial partners.
ORIDIS Biomed is a privately held company, based in Graz, Austria.
For further information, please visit ORIDIS Biomed’s website at
www.oridis-biomed.com
Company Contact:
Dr Peter Hecht, CEO
ORIDIS Biomed Forschungs- und Entwicklungs GmbH
Stiftingtalstrasse 3–5
A-8010 Graz, Austria
+43-316–325776
info@oridis-biomed.com
Media Contact:
Frank Butschbacher
IR/Communications
+43–650–7844940
office@butschbacher.net
